CN113397076A - 一种中药饮品组合物及其制备方法 - Google Patents
一种中药饮品组合物及其制备方法 Download PDFInfo
- Publication number
- CN113397076A CN113397076A CN202110713077.3A CN202110713077A CN113397076A CN 113397076 A CN113397076 A CN 113397076A CN 202110713077 A CN202110713077 A CN 202110713077A CN 113397076 A CN113397076 A CN 113397076A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- filtrate
- beverage composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 235000013361 beverage Nutrition 0.000 title claims description 43
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 33
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000000605 extraction Methods 0.000 claims abstract description 28
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 20
- 238000001914 filtration Methods 0.000 claims abstract description 19
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 16
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 16
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 16
- 239000008213 purified water Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- 241001165494 Rhodiola Species 0.000 claims abstract description 12
- 238000004806 packaging method and process Methods 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 8
- 235000015165 citric acid Nutrition 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims description 27
- 235000019534 high fructose corn syrup Nutrition 0.000 claims description 17
- 238000010992 reflux Methods 0.000 claims description 13
- 239000011362 coarse particle Substances 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 6
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 claims description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 235000008434 ginseng Nutrition 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000006188 syrup Substances 0.000 claims description 5
- 235000020357 syrup Nutrition 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000006866 deterioration Effects 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 235000019640 taste Nutrition 0.000 abstract description 12
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 abstract description 11
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000002929 anti-fatigue Effects 0.000 abstract description 5
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000002481 ethanol extraction Methods 0.000 abstract description 2
- 235000021433 fructose syrup Nutrition 0.000 abstract description 2
- 235000019629 palatability Nutrition 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 40
- 239000013642 negative control Substances 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 23
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 230000009182 swimming Effects 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 125000003147 glycosyl group Chemical group 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229920002527 Glycogen Polymers 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000037396 body weight Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000008083 Urea Assay Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- JBGYSAVRIDZNKA-NKECSCAMSA-N (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-17-[(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@]3(C)O[C@H](CC3)C(C)(C)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O JBGYSAVRIDZNKA-NKECSCAMSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- NFZYDZXHKFHPGA-UHFFFAOYSA-N 17alpha-hydroxygofruside Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(CO)O2)O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OC(C(O)=O)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NFZYDZXHKFHPGA-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- QXQFFGOMXYKNBA-UHFFFAOYSA-N Chikusetsusaponin V Natural products CC1(C)CCC2(CCC3C(=CCC4C3(C)CCC5C(C)(C)C(CCC45C)OC6OC(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O QXQFFGOMXYKNBA-UHFFFAOYSA-N 0.000 description 1
- NFZYDZXHKFHPGA-QQHDHSITSA-N Chikusetsusaponin-V Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NFZYDZXHKFHPGA-QQHDHSITSA-N 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000997135 Rhodiola crenulata Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- RBRANZURTULKJD-UHFFFAOYSA-N ginsenoside Ro Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(C)(C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(=O)O)C(C)(C)C5CCC34C)C2C1)C(=O)OC8OC(CO)C(O)C(O)C8O RBRANZURTULKJD-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/42—Preservation of non-alcoholic beverages
- A23L2/44—Preservation of non-alcoholic beverages by adding preservatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
本发明属于中药饮品领域,具体涉及一种中药饮品组合物,并进一步公开其制备方法。以红景天、西洋参为原料,采用醇提法,用乙醇提取等量混合的红景天和西洋参,再经浓缩、混合调配、过滤、灌封、灭菌、包装等工序制作而成。提取步骤简单、高效,以提取物中的红景天苷的含量为考察指标,经本发明的方案提取后,红景天苷平均含量达2.92mg/g生药,达到了良好的提取效果。而且,本发明仅采用红景天和西洋参两味有效成分,成分简单、明确,搭配辅料果葡糖浆、山梨酸钾、柠檬酸和纯化水,以提高适口性和稳定性。制备出的产品兼具红景天和西洋参抗疲劳的效果,且营养成分吸收效率高,口感好,服用方便,产品性质稳定,保质期长。
Description
技术领域
本发明属于中药饮品领域,具体涉及一种中药饮品组合物,并进一步公开其制备方法。
背景技术
随着生活节奏不断加快,社会竞争日益激烈,现代社会人们身体长期超负荷运转。疲劳成为困扰很多人的健康问题,每天忙碌的工作和生活,以肌肉活动为主的体力活动,或是以精神和思维活动为主的脑力活动,经过一定的时间和达到一定的程度都会出现活动能力的下降,表现为疲倦、肌肉酸痛或全身无力,这种现象就称为疲劳。疲劳是一种生理性现象,对人来说是一种保护性的机制。这是身体向我们发出应该休息的信号。如果对它不管不顾,身体就会受到损害,使人体的自身免疫力降低,容易诱发疾病,损害人们的身心健康。尤其随着年龄上升,体力趋于下降,身体各项机能代谢逐渐缓慢,对疲劳的调节能力变差,如不能及时缓解身体疲劳状态,长期以往,会导致机体免疫力和抵抗力下降,不仅影响健康,还会产生早衰,降低生活质量。
目前,市面所售的抗疲劳保健品多为营养物质补充类,这些物最主要包在糖、脂肪、蛋白质、氨基酸(支链氨基酸、芳香族氨基酸、谷氨酰胺、牛磺酸、肌酸)、B族维生素、VC、VE、左旋肉碱、微量元素(钙、磷、钾、钠、铁、硒、锌等)、水和电解质、丙酮酸等,由于这些营养素以补充机体的损失为主要目的,所以添加这类营养素的抗疲劳运动食品又称为营养强化食品,并不能称为真正意义上的保健食品。
中医药在消除疲劳和增强运动能力方面有其独特的优势。现已证实,中医中药和食疗药物不仅可以增加入体内的能量物质,而且有调节神经内分泌系统、加强代谢等作用,并可刺激体内激素的分泌与释放,增强心血管系统、消化系统以及造血系统、骨器系统等功能,延缓过度疲劳的产生。
虽然,现用于缓解体力疲劳的保健食品的种类繁多,但这些产品普遍存在成分种类繁多复杂,效果不明显的缺陷,同时,由于成分复杂导致保健食品价格昂贵,无法长时间服用,不能达到持续、系统的缓解体力疲劳的效果。而且,为达到预期疗效,现有抗疲劳保健品对有效成分大量添加,进一步造成产品成本过高的问题。因此,研制一种成分简单、有效、可长期服用的缓解体力疲劳的保健食品具有十分重要的意义。
发明内容
本发明所要解决的技术问题在于提供一种中药饮品组合物。仅采用红景天和西洋参两味有效成分,成分简单、明确,搭配辅料果葡糖浆、山梨酸钾、柠檬酸和纯化水,以提高适口性和稳定性。制备出的产品兼具红景天和西洋参抗疲劳的效果,且营养成分吸收效率高,口感好,服用方便,产品性质稳定,保质期长。
为实现上述目的,本发明提供了一种中药饮品组合物,按质量份数计,由以下成分组成:
红景天1-5份、西洋参1-5份、果葡糖浆6-10份、山梨酸钾0.2-0.8份、柠檬酸0.01-0.02份、纯化水70-100份。
在一优选的实施方式中,按质量份数计,由以下成分组成:
红景天2-4份、西洋参2-4份、果葡糖浆7-9份、山梨酸钾0.3-0.7份、柠檬酸0.01份、纯化水80-90份。
在另一优选的实施方式中,按质量份数计,由以下成分组成:
红景天3份、西洋参3份、果葡糖浆8份、山梨酸钾0.4份、柠檬酸0.01份、纯化水86份。
本发明所要解决的第二个技术问题在于提供上述中药饮品组合物的制备方法。以红景天、西洋参为原料,采用醇提法,用乙醇提取等量混合的红景天和西洋参,再经浓缩、混合调配、过滤、灌封、灭菌、包装等工序制作而成。提取步骤简单、高效,以提取物中的红景天苷的含量为考察指标,经本发明的方案提取后,红景天苷平均含量达2.92mg/g生药,达到了良好的提取效果。
为实现上述目的,本发明提供了一种中药饮品组合物的制备方法,包括以下步骤:
1)原料预处理:将红景天与西洋参分别依次进行净料、粉碎、过10目筛,制备成粗颗粒备用;
2)提取:将红景天粗颗粒和西洋参粗颗粒混合均匀,置于提取罐中,加入乙醇,回流并提取,收集滤液;
3)浓缩:将滤液静置沉降,再次过滤后,减压浓缩至密度为1.05-1.10g/ml的提取浸膏;
4)调配:加入果葡糖浆、山梨酸钾、柠檬酸和纯化水,搅拌均匀,用0.3-0.6μm滤膜过滤,得到中药饮品;
5)灌封杀菌灯检包装:将制备的中药饮品用灌封机灌封,采用湿热灭菌法处理,灯检包装后,即得具备商品化的中药饮品组合物。
在一优选的实施方式中,步骤1)中所述净料处理为:先将原料用纯化水冲洗干净,除去泥污杂质及劣质药材,再将原料晾干,确保原料无霉烂变质现象,无泥沙,无杂质。
在一优选的实施方式中,步骤2)中所述提取处理为:在混匀后的红景天-西洋参粗颗粒中加入其质量10倍的质量浓度为60%的乙醇溶液,常温回流1.5-2h,过滤,得到第一滤渣和第一滤液;
向前述第一滤渣中加入其质量8倍的质量浓度为60%的乙醇溶液,常温回流1.5-2h,过滤,得到第二滤渣和第二滤液;
向前述第二滤渣中加入其质量8倍的质量浓度为60%的乙醇溶液,常温回流1.5-2h,过滤,得到第三滤液;
收集混合第一滤液、第二滤液和第三滤液得到滤液。
在一优选的实施方式中,步骤3)中所述减压浓缩条件为:60-80℃,蒸汽压力≤0.3Mpa,真空度≥0.05Mpa,得到提取浸膏。
在一优选的实施方式中,步骤4)中所述滤膜为0.45μm滤膜。
在一优选的实施方式中,步骤5)中所述湿热灭菌法条件为:将灌封后的中药饮品在115℃温度条件下,灭菌时间在40-45min。
在一优选的实施方式中,制备出的一种中药饮品组合物产品规格为100ml/瓶,日服用量为每次1瓶,每日1次。
本发明的一种中药饮品组合物各原料作用如下:
1)红景天为景天科大花红景天Rhodiola crenulata(Hook.f.et Thoms.)H.Ohba的干燥根和根茎,秋季花茎凋枯后采挖,除去粗皮,洗净,晒干。味甘、苦,性平,归肺、心经。具有益气活血,通脉平喘之功。主要用于气虚血瘀,胸痹心痛,中风偏瘫,倦怠气喘。国内外对红景天属植物的化学成分研究较多,已先后从各种红景天中分离得到40多种化学成分,目前红景天属植物的化学成分主要有苷类、黄酮类、香豆素类、挥发油等,其中红景天苷和苷元酪醇是迄今研究最多的已知有效成分。由于红景天苷功效确切,常用来评价红景天属植物药用价值。
虽然,红景天对机体的功能作用己经得到科学的证明,但由于其中功效成分红景天苷含量相对较低,需食入较大量才能达到预期疗效,同时红景天植株主要为木质纤维素,人体不能消化吸收,口感极差,食用极不方便。
2)西洋参,西洋参为五加科植物西洋参Panax quinque folium L.的干燥根。味甘、微苦,性凉。归心、肺、肾经。具补气养阴、清热生津之功,用于气虚阴亏、内热、咳喘痰血、虚热烦倦、消渴、口燥咽干。药理研究表明,西洋参有抗疲劳、保护肝损伤、增强免疫、拉氧化等作用,主要化学成分有皂苷类、糖类、氨基酸类等。其中,人参皂苷已分离出的5种皂苷,分别为:人参皂苷Ro、Rb1、Rg1、Re和拟人参皂苷F11。西洋参皂苷是西洋参中最主要的有效成分之一,也是生理活性最显著的物质。
因此,本发明方案中将红景天与西洋参等量复配,混合均匀,一起采用醇提法,提取有效成分,制备成口服液。既可以减少使用其他原料,精简配方,又可以简化提取工艺,节约能耗。
3)果葡糖浆是由植物淀粉水解和异构化制成的淀粉糖晶,由葡萄糖和果糖组成,为无色黏稠状液体,常温下流动性好,无臭。果葡糖浆的最大优点在于含量相当数量(42%-90%)的果糖,因而在甜味特性上与其他甜味剂共同使用,具有优越的协同增效作用,可改善食品与饮料的口感,减少苦味和怪味。果葡糖浆的主要成分和性质接近于天然果汁,具有水果清香,味感方面,味觉甜度比蔗糖浓,且有清凉感,因为水果汁中的糖分主要也是果糖和葡萄糖。由于果葡糖浆的甜度与蔗糖相当,又有其特性,成本低于蔗糖。
4)柠檬酸是一种重要的有机酸,又名枸橼酸,无色晶体,常含一分子结晶水,无臭,有很强的酸味,易溶于水,常用于清凉饮料、果酱、水果和糕点等食品中,是一种常用的酸味剂。另外,柠檬酸还能增加苯甲酸、山梨酸等防腐剂的抗菌效果。
5)山梨酸钾为白色至浅黄色鳞片状结晶、晶体颗粒或晶体粉末,无臭或微有臭味,易溶于水,能有效地抑制霉菌、酵母菌和好氧性细菌的活性,还能防止肉毒杆菌、葡萄球菌、沙门氏菌等有害微生物的生长和繁殖,其防腐效果是同类产品苯甲酸钠的5-10倍,且抑菌效果在pH4.5时效果最佳。另外,山梨酸钾是一种不饱和脂肪酸盐,它可以被人体的代谢系统吸收而迅速分解为二氧化碳和水,在体内无残留,其毒性仅为食盐的1/2,是苯甲酸钠的1/40。此外,山梨酸钾对热稳定性较好,分解温度高达270℃。
因此,本发明方案中将果葡糖浆、柠檬酸复配山梨酸钾既能达到提味效果,掩盖西洋参特殊口味,又能提高中药饮品稳定性,延长产品货架期。
与现有技术相比,根据本发明的一种中药饮品组合物及其制备方法,具有如下优点:
1)本发明的一种中药饮品组合物主要原料为中药材,有效成分溶于水,适宜经提取后,添加适宜辅料制备成液体饮品。液体饮品具有适用人群范围广、质量稳定、服用方便、口感好、包装时尚等优点。而且,液体饮品无需崩解溶出度,生物利用度较好,利于吸收,效果更显著。
2)本发明的饮品仅采用红景天和西洋参作为有效成分,原料明确,添加量低,成本低,易于普及推广。
3)本发明的一种中药饮品组合物制备方法,工艺成熟稳定、易实现工业化、规模化生产。机械化生产,产量大,能耗低,易于控制卫生标准和生产条件。
具体实施方式
若未特别指明,实施例中所用技术手段为本领域技术人员所熟知的常规手段,所用原料均为市售商品。
除非另有特别说明,本发明中用到的各种原材料、试剂、仪器和设备等均可通过市场购买得到或者可通过现有方法制备得到。
在本发明中,重量份可以是μg、mg、g、kg等本领域公知的重量单位,也可以是其倍数,如1/10、1/100、10倍、100倍等。
实施例1
原料组成:红景天3g、西洋参3g、果葡糖浆8g、山梨酸钾0.4g、柠檬酸0.01g、纯化水86g。
制备方法:
1)原料预处理:将配方量的红景天与西洋参先将原料用纯化水冲洗干净,除去泥污杂质及劣质药材,再将原料晾干,确保原料无霉烂变质现象,无泥沙,无杂质;再分别粉碎、过10目筛,制备成粗颗粒备用;
2)提取:将红景天粗颗粒和西洋参粗颗粒混合均匀,置于提取罐中,在混匀后的红景天-西洋参粗颗粒中加入其质量10倍的质量浓度为60%的乙醇溶液,常温回流2h,过滤,得到第一滤渣和第一滤液;向前述第一滤渣中加入其质量8倍的质量浓度为60%的乙醇溶液,常温回流2h,过滤,得到第二滤渣和第二滤液;向前述第二滤渣中加入其质量8倍的质量浓度为60%的乙醇溶液,常温回流1.5-2h,过滤,得到第三滤液;收集混合第一滤液、第二滤液和第三滤液得到滤液;
3)浓缩:将滤液静置沉降,再次过滤后,在60-80℃,蒸汽压力≤0.3Mpa,真空度≥0.05Mpa的条件下,减压浓缩至6.09g的提取浸膏;
4)调配:加入配方量的果葡糖浆、山梨酸钾、柠檬酸和纯化水,搅拌均匀,用0.45μm滤膜过滤,得到中药饮品;
5)灌封杀菌灯检包装:将制备的中药饮品用灌封机灌封,将灌封后的中药饮品在115℃温度条件下,灭菌40-45min;灯检包装后,即得具备商品化的中药饮品组合物。
实施例2
为确定本发明中果葡糖浆和柠檬酸的用量,取实施例1的红景天、西洋参的添加量,原料经60%乙醇提取3次,每次2h,(溶媒倍数分别10:8:8),减压浓缩至相对密度1.05-1.10,提取后分别加入不同用量的果葡糖浆和柠檬酸,用纯化水混合调配,过滤后灌封灭菌。再选取30名具有感官评价基础知识的人员(男女各15名,年龄均在20-50岁之间)分别对中药饮品口感评分,以口感满意率为考察指标进行考察,具体试验结果见表1。
表1辅料用量的筛选
试验结果表明:当果葡糖浆800g、柠檬酸1.0g时,能满足多数人的口感要求,满意度较高。
实施例3
试验分别取9份实施例1配方量的红景天和西洋参混合粗颗粒,采用L9(34)的正交设计进行,按因素水平表(表2)的设计条件进行食用酒精回流提取,滤过,滤液减压回收食用酒精,浓缩至相对密度为1.10(70~80℃)的浸膏,以提取物中的红景天苷的含量为考察指标,进而确定本品最佳提取工艺。
表2因素水平表
表3正交实验表及实验结果
表4方差分析表
方差分析结果表明:以红景天苷含量为考察指标,影响提取工艺的因素作用顺序为:提取次数>酒精浓度>加醇量>提取时间,提取次数的影响具有显著性差异,最佳工艺为A3B2C3D3,即加8倍量的70%食用酒精,回流提取3次,每次3h。
但是实际生产过程中,发明人付出细致思考和大量创造性实验发现,如果在第一次提取时,溶剂倍数上调至10倍,第二次和第三次依然为8倍,则可用浓度为60%的乙醇,每次提取2h,达到相近似的效果。有效减少能源和试剂消耗,节能减排,缩短制备时间。并且,发明人补做了验证试验,结果如下:
验证试验
按前述确定的提取工艺条件进行三次重复性试验,试验结果如下:
表5验证试验结果
结果表明:三次重复性验证试验中,提取浸膏中红景天苷平均含量为2.92mg/g(生药),RSD值为3.19%,上述验证结果表明,该提取工艺稳定、可行。
实施例4
发明人根据生产经验及设备,拟采用的115℃灭菌温度,以灭菌后的样品微生物检验结果为考察指标,对灭菌时间进行了考察,实验数据总结如下:
表6微生物检验结果
由上述试验结果可知:115℃温度条件下,灭菌时间在40min-45min时,其微生物指标可以符合GB16740中微生物的指标要求,可以达到良好的灭菌效果。
试验例
将实施例1制备的中药饮品组合物进行功效学测试,依据《保健食品检验与评价技术规范(2003版)》内容进行试验,结果如下:
1.样品:由于相对于实验动物,本发明饮品人体摄入量较大,故将实施例1的配方用量制备出的饮品采用减压浓缩至5倍的浓缩液,即1mL样品相当于5mL实施例1的饮品。
2.实验动物:清洁级雄性昆明种小鼠150只,体重18-22g
3.剂量设计及配制:剂量设计:设2.50mL/kg.bw、1.67mL/kg.bw、0.83mL/kg.bw三个剂量组(分别相当于人体推荐用量的30倍、20倍、10倍),另设阴性对照组(蒸馏水)、糖基对照组(高剂量相对应浓度的果葡糖浆,蒸馏水配制)。样品配制:准确量取样品10.0mL、6.67mL、3.33mL,分别加蒸馏水至20mL,混匀,配制成浓度为50.0%、33.4%、16.7%的混悬液,备用。
4.试验方法:预游泳后选姿势正确雄性小鼠150只,共分三个试验组,每个试验组50只小鼠并随机分为5小组,各试验组均设三个剂量组和阴性对照组、糖基对照组,每组10只小鼠,试验一组为负重游泳试验,试验二组为血清尿素氮测定试验,试验三组为血乳酸测定试验。试验组四为肝糖原测定试验。按20mL/kg.bw每天经口给予受试样品一次,阴性对照组给予同体积蒸馏水,糖基对照组给予高剂量相对应浓度的果葡糖浆,用蒸馏水配制。连续30天。然后分别进行各项指标的测定,方法如下:
1)负重游泳试验:于末次给予受试样品后30分钟,将小鼠置于游泳箱中游泳,水深35cm,水温25℃,鼠尾根部负荷5%体重的铅皮。记录各组小鼠自游泳开始至死亡的时间,作为小鼠负重游泳时间,各剂量组结果与阴性对照组比较进行方差分析。死亡判断标准为:小鼠沉至游泳箱底并停止张口呼吸。若剂量组游泳时间明显长于阴性对照组游泳时间,且差异有显著性(P<0.05),可判定该受试样品有延长小鼠负重游泳时间的作用。
2)血清尿素氮测定:于末次给予受试样品后30分钟,在温度为30℃的水中不负重游泳90分钟,休息60分钟后拔眼球采血约0.5mL,分离血清后用全自动生化分析仪进行血清尿素氮测定,各剂量组结果与阴性对照组比较进行方差分析。若剂量组血清尿素含量明显低于阴性对照组,且差异有显著性(P<0.05),可判定该受试样品有减少疲劳小鼠尿素产生的作用。
3)肝糖原测定:于末次给予受试样品后30分钟处死动物,解剖取出肝脏,按试剂盒要求进行肝糖原测定,各剂量组结果与阴性对照组比较进行方差分析。肝糖原测定采用南京建成赛浩科技有限公司生产的试剂盒进行测定。若剂量组肝糖原含量明显高于阴性对照组,且差异有显著性(P<0.05),可判定该受试样品有促进小鼠肝糖原储备的作用。
4)血乳酸测定:于末次给予受试样品,30分钟后采血,然后小鼠在30℃水中不负重游泳10分钟,于游泳前、游泳后立即及游泳后休息20分钟,分别三次采血(内眦采血)测定血乳酸含量,以三个时间点血乳酸曲线下面积为指标,将各剂量组结果与阴性对照组比较进行方差分析。血乳酸测定采用试剂盒进行测定。若剂量组血乳酸曲线下面积明显小于阴性对照组,且差异有显著性(P<0.05),可判定该受试样品有减小小鼠运动后血乳酸曲线下面积的作用。
5.试验结果:
1)负重游泳试验
由表7可见,各剂量组小鼠各期体重及增重与阴性对照组、糖基对照组比较,差异均无显著性(P>0.05)。
由表8可见,各剂量组小鼠平均游泳时间均较阴性对照组游泳时间延长,且高剂量组与阴性对照组比较,差异有显著性(P1<0.01)。与糖基对照组比较,差异也具有显著性(P2<0.01)。结果表明,该样品有延长小鼠负重游泳时间的作用。
注:*表示与阴性对照组比较P1<0.05,#表示与糖基对照组比较P2<0.05。
2)小鼠血清尿素测定
由表9可见,各剂量组小鼠各期体重及增重与阴性对照组、糖基对照组比较,差异均无显著性(P>0.05)。
由表10可见,各剂量组小鼠血清尿素含量均少于阴性对照组,且高剂量组与阴性对照组比较,差异有显著性(P1<0.01)。与糖基对照组比较,差异也具有显著性(P2<0.01)。
注:**表示与阴性对照组比较P1<0.01,##表示与糖基对照组比较P2<0.01。
3)小鼠肝糖原测定
由表11可见,各剂量组小鼠各期体重及增重与阴性对照组、糖基对照组比较,差异均无显著性(P>0.05)。
由表12可见,各剂量组小鼠肝糖原含量均高于阴性对照组,且高剂量组与阴性对照组比较,差异有显著性(P1<0.01)。与糖基对照组比较,差异也具有显著性(P2<0.01)。
注:**表示与阴性对照组比较P1<0.01,##表示与糖基对照组比较P2<0.01。
4)小鼠血乳酸测定
由表13可见,各剂量组小鼠各期体重及增重与阴性对照组、糖基对照组比较,差异均无显著性(P>0.05)。
由表14可见,各剂量组小鼠三个时间点血乳酸曲线下面积均小于阴性对照组,且各剂量组与阴性对照组、糖基对照组比较,差异均无显著性(P>0.05)。结果表明,该受试样品无减小小鼠运动后血乳酸曲线下面积的作用。
总结:以本发明实施例1的配方及用量,按人体推荐量的30倍、20倍、10倍的剂量设计,给小鼠连续灌胃30天后进行各项指标测定,各剂量组与阴性对照组比较结果如下:
a)对小鼠体重的影响:各剂量组小鼠各期体重及增重与阴性对照组、糖基对照组比较,差异均无显著性(P>0.05)。
1)小鼠负重游泳试验:高剂量组可明显延长小鼠负重游泳时间,与阴性对照组、糖基对照组比较,差异有显著性(P<0.01)。
2)小鼠血清尿素测定:高剂量组可明显降低小鼠血清尿素含量,与阴性对照组、糖基对照组比较,差异有显著性(P<0.01)。
3)小鼠肝糖原测定:高剂量组能明显增加小鼠肝糖原的储备量,与阴性对照组、糖基对照组比较,差异有显著性(P<0.01)。
4)小鼠血乳酸测定:各剂量组血乳酸曲线下面积,与阴性对照组、糖基对照组比较,差异均无显著性(P>0.05)。
依据《保健食品检验与评价技术规范》(2003年版)中“缓解体力疲劳功能评价方法”可以判定,本发明制备的中药饮品组合物具有缓解体力疲劳功能。
显然,上述实施例仅仅是为清楚地说明所作的举例,而并非对实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (9)
1.一种中药饮品组合物,其特征在于,按质量份数计,由以下成分组成:
红景天1-5份、西洋参1-5份、果葡糖浆6-10份、山梨酸钾0.2-0.8份、柠檬酸0.01-0.02份、纯化水70-100份。
2.根据权利要求1所述的一种中药饮品组合物,其特征在于,按质量份数计,由以下成分组成:
红景天2-4份、西洋参2-4份、果葡糖浆7-9份、山梨酸钾0.3-0.7份、柠檬酸0.01份、纯化水80-90份。
3.根据权利要求1所述的一种中药饮品组合物,其特征在于,按质量份数计,由以下成分组成:
红景天3份、西洋参3份、果葡糖浆8份、山梨酸钾0.4份、柠檬酸0.01份、纯化水86份。
4.根据权利要求1-3任一项所述一种中药饮品组合物的制备方法,其特征在于,包括以下步骤:
1)原料预处理:将红景天与西洋参分别依次进行净料、粉碎、过10目筛,制备成粗颗粒备用;
2)提取:将红景天粗颗粒和西洋参粗颗粒混合均匀,置于提取罐中,加入乙醇,回流并提取,收集滤液;
3)浓缩:将滤液静置沉降,再次过滤后,减压浓缩至密度为1.05-1.10g/ml的提取浸膏;
4)调配:加入果葡糖浆、山梨酸钾、柠檬酸和纯化水,搅拌均匀,用0.3-0.6μm滤膜过滤,得到中药饮品;
5)灌封杀菌灯检包装:将制备的中药饮品用灌封机灌封,采用湿热灭菌法处理,灯检包装后,即得具备商品化的中药饮品组合物。
5.根据权利要求4所述一种中药饮品组合物的制备方法,其特征在于,步骤1)中所述净料处理为:先将原料用纯化水冲洗干净,除去泥污杂质及劣质药材,再将原料晾干,确保原料无霉烂变质现象,无泥沙,无杂质。
6.根据权利要求4所述一种中药饮品组合物的制备方法,其特征在于,步骤2)中所述提取处理为:在混匀后的红景天-西洋参粗颗粒中加入其质量10倍的质量浓度为60%的乙醇溶液,常温回流1.5-2h,过滤,得到第一滤渣和第一滤液;
向前述第一滤渣中加入其质量8倍的质量浓度为60%的乙醇溶液,常温回流1.5-2h,过滤,得到第二滤渣和第二滤液;
向前述第二滤渣中加入其质量8倍的质量浓度为60%的乙醇溶液,常温回流1.5-2h,过滤,得到第三滤液;
收集混合第一滤液、第二滤液和第三滤液得到滤液。
7.根据权利要求4所述一种中药饮品组合物的制备方法,其特征在于,步骤3)中所述减压浓缩条件为:60-80℃,蒸汽压力≤0.3Mpa,真空度≥0.05Mpa,得到提取浸膏。
8.根据权利要求4所述一种中药饮品组合物的制备方法,其特征在于,步骤4)中所述滤膜为0.45μm滤膜。
9.根据权利要求4所述一种中药饮品组合物的制备方法,其特征在于,步骤5)中所述湿热灭菌法条件为:将灌封后的中药饮品在115℃温度条件下,灭菌时间在40-45min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110713077.3A CN113397076A (zh) | 2021-06-25 | 2021-06-25 | 一种中药饮品组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110713077.3A CN113397076A (zh) | 2021-06-25 | 2021-06-25 | 一种中药饮品组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113397076A true CN113397076A (zh) | 2021-09-17 |
Family
ID=77679443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110713077.3A Pending CN113397076A (zh) | 2021-06-25 | 2021-06-25 | 一种中药饮品组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113397076A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657354A (zh) * | 2012-05-18 | 2012-09-12 | 通德集团有限公司 | 一种含有大花红景天的饮料及其制备方法 |
CN103519308A (zh) * | 2013-10-22 | 2014-01-22 | 浙江小二黑食品有限公司 | 一种多功能中药功能饮品及其制备方法 |
CN103535801A (zh) * | 2012-07-09 | 2014-01-29 | 钟虹光 | 一种具有缓解体力疲劳和提高缺氧耐受力的保健饮料 |
CN104256600A (zh) * | 2014-09-30 | 2015-01-07 | 广州市香雪制药股份有限公司 | 保健营养组合物及其制备方法与应用 |
CN106108016A (zh) * | 2016-06-28 | 2016-11-16 | 广州市赛健生物科技有限公司 | 一种缓解体力疲劳的保健食品及其制备方法 |
CN107811179A (zh) * | 2017-10-24 | 2018-03-20 | 青海鑫池源生物科技开发有限公司 | 一种红景天饮料及其制备方法 |
CN113812548A (zh) * | 2020-06-18 | 2021-12-21 | 青海清华博众生物技术有限公司 | 西洋参抗疲劳饮料及其制备方法 |
-
2021
- 2021-06-25 CN CN202110713077.3A patent/CN113397076A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657354A (zh) * | 2012-05-18 | 2012-09-12 | 通德集团有限公司 | 一种含有大花红景天的饮料及其制备方法 |
CN103535801A (zh) * | 2012-07-09 | 2014-01-29 | 钟虹光 | 一种具有缓解体力疲劳和提高缺氧耐受力的保健饮料 |
CN103519308A (zh) * | 2013-10-22 | 2014-01-22 | 浙江小二黑食品有限公司 | 一种多功能中药功能饮品及其制备方法 |
CN104256600A (zh) * | 2014-09-30 | 2015-01-07 | 广州市香雪制药股份有限公司 | 保健营养组合物及其制备方法与应用 |
CN106108016A (zh) * | 2016-06-28 | 2016-11-16 | 广州市赛健生物科技有限公司 | 一种缓解体力疲劳的保健食品及其制备方法 |
CN107811179A (zh) * | 2017-10-24 | 2018-03-20 | 青海鑫池源生物科技开发有限公司 | 一种红景天饮料及其制备方法 |
CN113812548A (zh) * | 2020-06-18 | 2021-12-21 | 青海清华博众生物技术有限公司 | 西洋参抗疲劳饮料及其制备方法 |
Non-Patent Citations (2)
Title |
---|
崔山风,主编: "《保健食品制剂技术》", 31 July 2010, 中国医药科技出版社 * |
杨红霞,主编: "《饮料加工技术》", 28 February 2015, 重庆大学出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101433188B1 (ko) | 아미노산, 활성종합비타민 및 한방생약재를 함유하는 숙취해소용 조성물 및, 그 제조방법 | |
KR101301094B1 (ko) | 숙취해소 또는 간 기능 개선용 조성물 | |
CN105639525A (zh) | 护肝排毒果蔬酵素及其制备方法 | |
KR101322230B1 (ko) | 수액을 포함하는 숙취 해소 음료 및 이의 제조방법 | |
CN108404019A (zh) | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 | |
KR20070105486A (ko) | 간 기능 개선과 숙취해소용 차 및 그 제조방법 | |
CN101396115B (zh) | 一种低聚木糖健胃润肠口服液及其制备方法 | |
CN104336174A (zh) | 一种红景天奶醋绿茶保健饮料 | |
CN111375049B (zh) | 一种解酒保肝的组合物及其制备方法和应用 | |
KR101371143B1 (ko) | 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물 | |
KR101394358B1 (ko) | 숙취 해소용 조성물 | |
CN101380128A (zh) | 竹葵多功能保健饮料及制法 | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
CN101884408B (zh) | 一种银杏叶浸提液及其制备方法 | |
CN106924548A (zh) | 一种缓解疲劳的药物及制备方法 | |
CN110279052A (zh) | 一种提高免疫力的果蔬酵素饮料及其制备方法 | |
CN110810693A (zh) | 一种含有显齿蛇葡萄的饮料组合物及其制备方法 | |
KR20130130131A (ko) | 흑마늘 발효 식초 조성물 및 그 제조방법 | |
KR101034986B1 (ko) | 혼합 생약추출물을 유효성분으로 함유하는 숙취해소용 조성물 | |
CN113397076A (zh) | 一种中药饮品组合物及其制备方法 | |
KR102127411B1 (ko) | 복합 천연 추출물을 함유하는 간기능 보호 및 숙취해소용 조성물 | |
CN109157548B (zh) | 一种具有抗疲劳和壮阳功能的组合物及制备方法 | |
KR101391647B1 (ko) | 항비만 조성물 | |
KR20050100890A (ko) | 오가피 및 녹차 추출물을 함유하는 숙취해소용 조성물 | |
CN1082353C (zh) | 一种含雪莲的生物菌饮料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210917 |